Dermata Therapeutics
DRMA
4 hedge funds and large institutions have $10.6K invested in Dermata Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.7% less ownership
Funds ownership: 0.74% → 0.04% (-0.7%)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
86% less capital invested
Capital invested by funds: $78.3K → $10.6K (-$67.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$3.98K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.31K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$66.9K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$418 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $4.74K | +$2.31K | +116 | +67% |
|
|
2
Wells Fargo
San Francisco,
California
| $3.35K | +$3.98K | +200 | +4,000% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2.46K | -$418 | -21 | -12% |
|
|
4
Bank of America
Charlotte,
North Carolina
| $16 | +$20 | +1 | New |
|
|
AC
5
Armistice Capital
New York
| – | -$66.9K | -2,800 | Closed |
|
|
6
Acadian Asset Management
Boston,
Massachusetts
| – | -$3K | -128 | Closed |
|
DRMA Hedge Fund Activity: Q3 2024 in Review
4 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q3 2024, worth a combined $10.6K — down 86% from $78.3K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DRMA and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Wells Fargo, adding an estimated $3.98K. The largest seller was Armistice Capital, exiting entirely with an estimated $66.9K sold.
- 4 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2024, down from 5 in Q2 2024.
- Funds reported $10.6K of Dermata Therapeutics stock for Q3 2024, down 86% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Dermata Therapeutics buyer in Q3 2024 was Wells Fargo, an estimated $3.98K added.
- The largest Dermata Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $66.9K sold.
Based on aggregated 13F filings for Q3 2024.